BRIEF: Biotis gets Bristol-Myers distribution deal: Biotis will initially market five brand drugs.

Jul 22, 2008 (Globes - McClatchy-Tribune Information Services via COMTEX) -- BMY | Quote | Chart | News | PowerRating -- Biotis Ltd. has obtained an exclusive marketing deal from Bristol-Myers Squibb Co. (NYSE:BMY) for selected products in Israel. Industry sources estimate that the long-term agreement is worth hundreds of millions of shekels a year.

Biotis won a tender in which a large number of Israeli companies participated. Biotis will initially market five life-saving and life-extending brand drugs for patients with severe or terminal illnesses. Some of these drugs have no equivalents authorized for marketing in Israel.

The drugs are Baraclude for hepatitis B, Ixempra for early-stage breast cancer, Orcencia for rheumatoid arthritis, Reyataz for AIDS, and Sprycel for advanced leukemia in adults. All these drugs are undergoing registration procedures and will be submitted for inclusion in the basket of healthcare products in 2009.

To see more of the Globes or to subscribe to the newspaper, go to http://www.globes.co.il. Copyright (c) 2008, Globes, Tel Aviv, Israel Distributed by McClatchy-Tribune Information Services. For reprints, email tmsreprints@permissionsgroup.com, call 800-374-7985 or 847-635-6550, send a fax to 847-635-6968, or write to The Permissions Group Inc., 1247 Milwaukee Ave., Suite 303, Glenview, IL 60025, USA.

Morning Coffee with TradingMarkets -- Free Newsletter

More News:   Market Updates | Stock Alerts | All Trading News | Stock Index